AI Article Synopsis
- PD-ECGF, also known as thymidine phosphorylase, can promote the growth of new blood vessels, potentially benefiting conditions related to chronic limb ischemia, which affects blood flow in the legs.
- In an experiment on rabbits, researchers injected a gene for PD-ECGF/TP into leg muscles after surgically resecting the femoral arteries, resulting in improved blood pressure and vascular growth in the treatment group compared to control groups.
- The study concluded that the overexpression of PD-ECGF/TP significantly enhanced blood vessel formation and limb perfusion, suggesting its potential as a therapeutic option for peripheral arterial disease.
Article Abstract
Objectives: Platelet-derived endothelial cell growth factor (PD-ECGF) is identical to thymidine phosphorylase (TP), and it can induce angiogenesis, including arteriogenesis, in chronically ischemic canine myocardium. Because its effect on peripheral arterial disease has not been elucidated, we investigated whether overexpression of PD-ECGF/TP could ameliorate chronic limb ischemia in rabbits.
Methods: Left femoral arteries were resected from 24 male rabbits. After 10 days, a plasmid vector containing human PD-ECGF/TP complimentary DNA was injected into 10 sites in the adductor muscles. Control groups received either the LacZ plasmid vector or saline vehicle only (n = 8 per group). Blood pressure was measured in the calf before surgery, at the onset of ischemia, 10 days later, and 20 and 30 days after gene transfer. Collateral vessel development and limb perfusion were assessed by angiography, and resected tissues underwent molecular and histologic examination.
Results: In the PD-ECGF/TP group, human PD-ECGF/TP messenger RNA and protein were still detected at 30 days after treatment. Calf blood pressure decreased significantly after femoral artery resection in all three groups. It subsequently showed a greater increase in the PD-ECGF/TP group than in either control group, and the difference was significant at 20 days after treatment (PD-ECGF/TP, 97.4 +/- 7.4; LacZ, 58.6 +/- 6.9; saline, 41.3 +/- 3.6). Immunohistochemical staining demonstrated an increased ratio of capillaries and arterioles to muscle fibers in the PD-ECGF/TP group (2.14 +/- 0.13 and 1.51 +/- 0.06), but not in the LacZ group (1.39 +/- 0.04 and 0.71 +/- 0.05) or the saline group (1.34 +/- 0.05 and 0.71 +/- 0.04, P < .01). The angiographic score was higher in the PD-ECGF/TP group (0.96 +/- 0.08) than in the LacZ group (0.50 +/- 0.02) or saline group (0.51 +/- 0.03) at 30 days after gene transfer (P < .01).
Conclusions: This study demonstrated that PD-ECGF/TP gene transfer induced angiogenesis and decreased ischemia in a rabbit hindlimb model by promoting arteriogenesis, suggesting that targeting this gene may be a promising therapeutic strategy for peripheral vascular disease.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jvs.2006.07.051 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Angiogenic biomarkers in children with congenital heart disease: possible implications.
Ital J Pediatr
April 2010
Medical Biochemistry Department, Faculty of Medicine, Assiut University, Assiut, (71515), Egypt.
Background: Vascular endothelial growth factor (VEGF), platelet derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP) and leptin are known as potent angiogenic factors The objective of the study was to evaluate these angiogenic factors VEGF, PD-ECGF/TP and leptin in children with congenital heart disease (CHD) and the factors that lead to angiogenesis in such cases.
Methods: Sixty CHD children were studied and divided into two groups (n=30); cyanotic-CHD (C-CHD) and acyanotic-CHD (A-CHD). Twenty five healthy children were included as controls.
Adventitial delivery of platelet-derived endothelial cell growth factor gene prevented intimal hyperplasia of vein graft.
J Vasc Surg
December 2008
Division of Cardiothoracic Surgery, Second Departments of Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Article Synopsis
- The study explored the effects of the PD-ECGF/TP gene on preventing vein graft failure by inhibiting the migration and proliferation of vascular smooth muscle cells (VSMCs).
- In the experiment involving 68 female rabbits, a poloxamer hydrogel containing various concentrations of trypsin was used to enhance gene transfer efficiency to the vein grafts before assessing intimal thickness over two time points.
- Results indicated that the treating with PD-ECGF/TP significantly reduced intimal thickness and VSMC proliferation compared to controls, demonstrating its potential effectiveness in reducing intimal hyperplasia in vascular grafts.
Platelet-derived endothelial cell growth factor gene therapy for limb ischemia.
J Vasc Surg
December 2006
Second Department of Surgery, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Article Synopsis
- PD-ECGF, also known as thymidine phosphorylase, can promote the growth of new blood vessels, potentially benefiting conditions related to chronic limb ischemia, which affects blood flow in the legs.
- In an experiment on rabbits, researchers injected a gene for PD-ECGF/TP into leg muscles after surgically resecting the femoral arteries, resulting in improved blood pressure and vascular growth in the treatment group compared to control groups.
- The study concluded that the overexpression of PD-ECGF/TP significantly enhanced blood vessel formation and limb perfusion, suggesting its potential as a therapeutic option for peripheral arterial disease.
Gene therapy for chronic myocardial ischemia using platelet-derived endothelial cell growth factor in dogs.
Am J Physiol Heart Circ Physiol
January 2005
Second Department of Surgery, Faculty of Medical Sciences, University of Fukui, 23-3 Shimoaizuki, Matsuoka-Cho, Yoshida-Gun, Fukui 9101193, Japan.
Platelet-derived endothelial cell growth factor (PD-ECGF), also known as thymidine phosphorylase (TP), has been reported to possess angiogenic activity and to inhibit apoptosis. This study was performed to determine whether PD-ECGF/TP can be used to ameliorate chronic myocardial ischemia. Myocardial ischemia was created in 40 mongrel dogs by placement of an ameroid constrictor on the proximal left anterior descending coronary artery (LAD).
View Article and Find Full Text PDFThymidine phosphorylase inhibits apoptosis induced by cisplatin.
Biochem Biophys Res Commun
February 2003
Department of Cancer Chemotherapy, Institute for Cancer Research, Faculty of Medicine, Kagoshima University, Sakuragaoka 8-35-1, Kagoshima 890, Japan.
An angiogenic factor, platelet-derived endothelial cell growth factor/thymidine phosphorylase (PD-ECGF/TP), stimulates the chemotaxis of endothelial cells and confers resistance to apoptosis induced by hypoxia. 2-Deoxy-D-ribose, a degradation product of thymidine generated by TP, partially prevents hypoxia-induced apoptosis. TP is expressed at higher levels in tumor tissues compared to the adjacent non-neoplastic tissues in a variety of human carcinomas.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!